PAIRED ‐PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine (DTG/3TC): a sub‐analysis of people with HIV (PWH) switching from bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in the United States
Call 1-888-226-8434
Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)
Report an Adverse Event
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at https://gsk.public.reportum.com or 1-877-844-8872, or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.
This site is intended for US Healthcare Professionals Only. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies.
©2025 ViiV Healthcare group of companies or its licensor. Produced in USA. February 2025